Mandate

Vinge advises in connection with the sale of Fiskarhedenvillan

March 17, 2020 M&A

Vinge has advised Litorina and other shareholders in connection with the sale of Fiskarhedenvillan to the company’s CEO and a group of industrial partners.

Fiskarhedenvillan sells residential properties primarily to private individuals in Sweden, Denmark and Finland and has a turnover of approximately SEK 700 million on an annual basis.

Vinge’s team primarily consisted of Johan WinnerbladJoacim RydergårdAnna ThomsOlivia BeldingRikard LindahlWilliam KågeLouise Brorsson Salomon and Viktoria Owetz Leyva.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025